Selective modulation of BACE1 cleavage activity toward APP by altering the glycosylation of BACE1 is considered a promising AD therapeutic modality.[51] However, previous inhibitors designed to target BACE1 activity often interfere with its processing of other substrates, leading to severe side effects. Here, APP is linked to Alzheimer disease.